Diclofenac injection - IBSA

Drug Profile

Diclofenac injection - IBSA

Alternative Names: Akis; Diclofenac HPBCD; Dicloin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBSA
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain; Back pain; Inflammatory pain; Musculoskeletal pain; Postoperative pain; Renal colic
  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in Switzerland (IV, Injection)
  • 01 Dec 2015 IBSA Biochemical completes a phase I trial in Pain (In volunteers) in Switzerland (IV) (ISRCTN20012465)
  • 01 May 2013 IBSA completes a phase II trial in Postoperative pain following dental surgery in the United Kingdom (NCT01706588)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top